When Standard Pancreatic Cancer Treatments Weren't Enough

Pancreatic cancer patient Rachelle Gardner accessed the investigational therapy daraxonrasib through an FDA-authorized Expanded Access Program at City of Hope Chicago, following exhaustion of standard treatments. Daraxonrasib is a KRAS-targeted therapy recently FDA approved, with City of Hope as a key clinical trial site and operator of a national clinical trials model allowing simultaneous trial and expanded access program launches.

This Wire brief sits within Fusion42's coverage of Biotech, and 50 sources have reported it between 26 Aug 2026 and 3 Sep 2026.